Unnamed: 0,title,date,stock,sentiment
989756.0,Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates,2020-06-01 16:00:00-04:00,PCRX,neutral
989757.0,"Benzinga's Top Upgrades, Downgrades For May 27, 2020",2020-05-27 09:35:00-04:00,PCRX,positive
989758.0,Guggenheim Initiates Coverage On Pacira BioSciences with Neutral Rating,2020-05-27 06:16:00-04:00,PCRX,neutral
989759.0,"Stifel Maintains Hold on Pacira BioSciences, Lowers Price Target to $48",2020-05-08 13:41:00-04:00,PCRX,negative
989760.0,"SVB Leerink Maintains Outperform on Pacira BioSciences, Raises Price Target to $45",2020-05-08 06:31:00-04:00,PCRX,neutral
989761.0,"Pacira BioSciences Q1 EPS $0.530 Beats $0.320 Estimate, Sales $105.684M Beat $102.970M Estimate",2020-05-07 08:27:00-04:00,PCRX,neutral
989762.0,"Pacira BioSciences Q1 EPS $0.530 Beats $0.320 Estimate, Sales $105.700M Beat $102.970M Estimate",2020-05-07 08:05:00-04:00,PCRX,neutral
989763.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,PCRX,negative
989764.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,PCRX,neutral
989765.0,"Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $52",2020-04-30 06:42:00-04:00,PCRX,negative
989766.0,Pacira BioSciences shares are trading higher after Northland Capital Markets initiated coverage on the stock with an Outperform market and announced a price target of $50 per share.,2020-04-07 15:21:00-04:00,PCRX,positive
989767.0,"Northland Capital Markets Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target to $50",2020-04-07 12:17:00-04:00,PCRX,neutral
989768.0,Shares of several healthcare companies are trading higher amid optimism that coronavirus cases in Asia are potentially easing. Global slowing cases could raise hopes of a sooner return to spending and economic activity. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic.,2020-04-07 07:48:00-04:00,PCRX,positive
989769.0,"The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test",2020-03-24 08:20:00-04:00,PCRX,negative
989770.0,"Benzinga's Top Upgrades, Downgrades For March 20, 2020",2020-03-20 10:15:00-04:00,PCRX,positive
989771.0,"SVB Leerink Upgrades Pacira BioSciences to Outperform, Lowers Price Target to $44",2020-03-20 08:59:00-04:00,PCRX,negative
989772.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,PCRX,neutral
989773.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,PCRX,positive
989774.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,PCRX,neutral
989775.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,PCRX,negative
989776.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,PCRX,negative
989777.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,PCRX,negative
989778.0,"HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Raises Price Target to $63",2020-02-24 07:04:00-05:00,PCRX,neutral
989779.0,"Pacira BioSciences Q4 Adj. EPS $0.56 Beats $0.44 Estimate, Sales $122.424M Beat $121.28M Estimate",2020-02-20 08:10:00-05:00,PCRX,neutral
989780.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,PCRX,negative
989781.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,PCRX,positive
989782.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-11 10:17:00-05:00,PCRX,neutral
989783.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,PCRX,positive
989784.0,"SunTrust Robinson Humphrey Initiates Coverage On Pacira BioSciences with Buy Rating, Announces $60 Price Target",2020-01-24 06:33:00-05:00,PCRX,neutral
989785.0,"Pacira Biosciences Shares Unaffected After Hours As Hearing SunTrust Initiated Stock With Buy Rating, $60 Price Target",2020-01-23 16:29:00-05:00,PCRX,positive
989786.0,Pacira Biosciences Sees FY19 Sales $421M vs $418.1M Estimate,2020-01-09 07:33:00-05:00,PCRX,neutral
989787.0,EXPAREL Achieves Primary And Key Secondary Endpoints In Phase 4 CHOICE Study In Cesarean Section Patients,2020-01-07 07:32:00-05:00,PCRX,neutral
989788.0,Pacira BioSciences Announces Results From Phase 3 PLAY Study Of EXPAREL In Pediatric Patients; Says Findings Were Consistent With Overall Safety Profiles For Adult Patients With No Safety Concerns Identified,2019-12-17 07:44:00-05:00,PCRX,positive
989789.0,Pacira BioSciences Reiterated FY19 Exparel Sales $400M - $410M & Iovera Sales $8M - 10M,2019-11-07 09:46:00-05:00,PCRX,neutral
989790.0,"Pacira BioSciences Q3 EPS $0.48 Beats $0.33 Estimate, Sales $104.685M Miss $104.89M Estimate",2019-11-07 09:40:00-05:00,PCRX,negative
989791.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,PCRX,negative
989792.0,"Benzinga's Top Upgrades, Downgrades For November 6, 2019",2019-11-06 09:56:00-05:00,PCRX,positive
989793.0,"BTIG Research Initiates Coverage On Pacira BioSciences with Buy Rating, Announces $56 Price Target",2019-11-06 06:39:00-05:00,PCRX,neutral
989794.0,55 Biggest Movers From Yesterday,2019-09-26 04:34:00-04:00,PCRX,neutral
989795.0,34 Stocks Moving In Wednesday's Mid-Day Session,2019-09-25 12:02:00-04:00,PCRX,neutral
989796.0,Pacira BioSciences Trades Higher After Joining S&P SmallCap 600,2019-09-25 08:37:00-04:00,PCRX,neutral
989797.0,23 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-09-25 08:17:00-04:00,PCRX,neutral
989798.0,24 Stocks Moving in Wednesday's Pre-Market Session,2019-09-25 07:46:00-04:00,PCRX,neutral
989799.0,Pacira BioSciences shares are trading higher after the stock was added to the S&P SmallCap 600 index.,2019-09-25 07:16:00-04:00,PCRX,positive
989800.0,"The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug",2019-09-25 07:13:00-04:00,PCRX,positive
989801.0,"S&P Dow Jones Announces Pacira BioSciences Set to Join S&P SmallCap 600, Will Replace Shutterfly",2019-09-24 17:15:00-04:00,PCRX,positive
989802.0,Pacira BioSciences Reports Completed Enrollment In Multicenter Registration Study Of EXPAREL In Pediatric Patients,2019-09-17 07:31:00-04:00,PCRX,neutral
989803.0,Pacira BioSciences Guides FY19 Exparel Net Product Sales Of $400M-$410M; Guides FY19 Iovera Net Product Sales Of $8M-$10M,2019-08-08 09:10:00-04:00,PCRX,neutral
989804.0,"Pacira BioSciences Q2 EPS $0.41 Beats $0.34 Estimate, Sales $102.6M Beat $100.52M Estimate",2019-08-08 09:08:00-04:00,PCRX,neutral
989805.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,PCRX,neutral
989806.0,40 Healthcare Stocks Moving In Friday's After-Market Session,2019-07-29 04:25:00-04:00,PCRX,neutral
989807.0,Pacira BioSciences 13D Shows Consonance Capital Management Holds 6.8% Stake In Co.; Firm Had Previously Held 7.8% Stake,2019-07-10 15:53:00-04:00,PCRX,neutral
989808.0,Pacira BioSciences Says New Retrospective Analysis Shows EXPAREL Is Associated With Significantly Less Opioid Use Following Third Molar Extraction,2019-06-26 07:32:00-04:00,PCRX,neutral
989809.0,Pacira BioSciences Announces Validation Of EXPAREL Marketing Authorization Application From European Medicines Agency,2019-06-25 07:32:00-04:00,PCRX,neutral
989810.0,Pacira BioSciences Names Max Reinhardt Pres,2019-06-19 07:31:00-04:00,PCRX,neutral
989811.0,Pacira BioSciences Highlights New Data Showing Use Of EXPAREL Was Associated With Improved Clinical And Economic Outcomes Following Hip Replacement Surgery,2019-06-12 07:34:00-04:00,PCRX,positive
989812.0,"Barclays Initiates Coverage On Pacira BioSciences with Overweight Rating, Announces $52 Price Target",2019-06-11 07:07:00-04:00,PCRX,negative
989813.0,Pacira Highlights Publication Of EXPAREL Pivotal Study As Single-Dose Interscalene Brachial Plexus Nerve Block in Patients Undergoing Shoulder Surgery In 'Pain Medicine',2019-06-04 07:33:00-04:00,PCRX,negative
989814.0,"Mizuho Upgrades Pacira Pharmaceuticals, Inc. - Common Stock to Neutral, Raises Price Target to $38",2019-05-06 11:29:00-04:00,PCRX,neutral
989815.0,Pacira Shares Spike Above $47 Level On Heavy Volume; Hearing Stifel Upgraded Stock In Mid-Day Call,2019-05-02 13:24:00-04:00,PCRX,positive
989816.0,Pacira BioSciences Sees FY19 EXPAREL Sales $400M-$410M,2019-05-02 09:05:00-04:00,PCRX,neutral
989817.0,"Pacira Pharmaceuticals Q1 EPS $0.22 Misses $0.26 Estimate, Sales $91.313M Miss $92.1M Estimate",2019-05-02 09:03:00-04:00,PCRX,negative
989818.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,PCRX,positive
989819.0,60 Biggest Movers From Yesterday,2019-05-02 06:10:00-04:00,PCRX,neutral
989820.0,46 Stocks Moving In Wednesday's Mid-Day Session,2019-05-01 13:24:00-04:00,PCRX,neutral
989821.0,Pacira BioSciences shares are trading higher after competitor Heron Therapeutics' marketing application for a pain treatment was rejected by the FDA.,2019-05-01 09:15:00-04:00,PCRX,negative
989822.0,Pacira Biosciences Shares Spike ~12% Premarket Following Complete Response Letter From Heron Therapeutics For Its Postoperative Pain Treatment; BZ NOTE: Pacira Has A Competing Drug Candidate,2019-05-01 08:08:00-04:00,PCRX,neutral
989823.0,Pacira Highlights EXPAREL Data,2019-03-13 07:34:00-04:00,PCRX,neutral
989824.0,"Pacira To Acquire MyoScience, Adding FDA-approved Ioveraº System For Non-Opioid Pain Control",2019-03-05 07:04:00-05:00,PCRX,negative
989825.0,51 Stocks Moving In Thursday's Mid-Day Session,2019-02-28 12:28:00-05:00,PCRX,neutral
989826.0,"Pacira Pharmaceuticals Q4 EPS $0.47 Beats $0.28 Estimate, Sales $95.1M Beat $93.69M Estimate",2019-02-28 08:08:00-05:00,PCRX,neutral
989827.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,PCRX,neutral
989828.0,"Pacira Announces Start Of Commercial Production At New EXPAREL Facility, expected To Double Co.'s Manufacturing Capacity",2019-02-12 07:37:00-05:00,PCRX,neutral
989829.0,Mizuho Downgrades Pacira Pharmaceuticals to Underperform,2019-02-01 08:59:00-05:00,PCRX,neutral
989830.0,"Pacira Pharmaceuticals, Inc. Reports Its Phase 4 Study Of EXPAREL Achieved Primary Endpoint, Showed Statistically Significant Reductions In Opioid Consumption And Pain Scores In C-Section Patients",2019-01-16 07:31:00-05:00,PCRX,negative
989831.0,Pacira Reports Preliminary 2018 Net EXPAREL Sales Of $331M And Q4 Net EXPAREL Sales Of $94M,2019-01-03 07:32:00-05:00,PCRX,neutral
989832.0,Pacira Reports Prelim. 2018 Net EXPAREL Sales Of $331M,2019-01-03 07:32:00-05:00,PCRX,neutral
989833.0,Pacira Pharmaceuticals Highlights Publication Of Data Showing Reductions In Postsurgical Pain And Opioid Requirements With EXPAREL In Cesarean Section Patients,2018-12-12 07:32:00-05:00,PCRX,negative
989834.0,Pacira Pharmaceuticals CMO Presents At FDA Advisory Committee Meeting Focused On Assessment Of Opioid-Sparing Outcomes In Clinical Trials,2018-11-16 07:31:00-05:00,PCRX,positive
989835.0,"UPDATE: Pacira Says Product-Specific C-Code For Ambulatory Surgical Center Procedures, D-Code For Dental Procedures To Take Effect Jan. 1, 2019",2018-11-02 14:14:00-04:00,PCRX,neutral
989836.0,UPDATE: Pacira Pharma Says New Reimbursement Model Will Provide Payemtn For EXPAREL At Average Sales Price +6%,2018-11-02 14:13:00-04:00,PCRX,neutral
989837.0,"Pacira Pharma Reports Centers For Medicare, Medicaid Services, American Dental Association Have Established New Reimbursement for EXPAREL",2018-11-02 14:13:00-04:00,PCRX,neutral
989838.0,"JP Morgan Maintains Neutral on Pacira Pharmaceuticals, Raises Price Target to $50",2018-11-02 12:50:00-04:00,PCRX,positive
989839.0,"BMO Capital Maintains Market Perform on Pacira Pharmaceuticals, Raises Price Target to $47",2018-11-02 11:05:00-04:00,PCRX,neutral
989840.0,Pacira Pharmaceuticals Raises FY2018 Sales Guidance from $300.0M-310.0M to $325.0M-330.0M vs $326.84M Est,2018-11-01 09:00:00-04:00,PCRX,neutral
989841.0,"Pacira Pharmaceuticals, Inc. Q3 EPS $0.31 Beats $0.08 Estimate, Sales $83.448M Beat $80.18M Estimate",2018-11-01 08:58:00-04:00,PCRX,neutral
989842.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,PCRX,negative
989843.0,Aetna To Offer Expanded Coverage For Pacira Pharmaceuticals' EXPAREL In Select Ambulatory Surgical Centers,2018-10-30 07:50:00-04:00,PCRX,neutral
989844.0,"Aetna To Offer Expanded Coverage For Its Exparel In Select Ambulatory Surgical Centers, Will Reimburse For Use In Florida, New Jersey",2018-10-30 07:38:00-04:00,PCRX,neutral
989845.0,Pacira Pharmaceuticals 13D Shows Consonance Capital Management Cut Stake From ~3.75M Shares To ~3.65M Shares,2018-10-22 17:11:00-04:00,PCRX,positive
989846.0,FDA Commissioner Scott Gottlieb Issues Statement On 'new efforts to advance the development of generic copies of complex drugs to improve patient access to medicines',2018-10-09 11:19:00-04:00,PCRX,positive
989847.0,"Stocks Which Set New 52-Week High Yesterday, September 19th",2018-09-20 11:24:00-04:00,PCRX,neutral
989848.0,"The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut",2018-09-20 09:02:00-04:00,PCRX,positive
989849.0,"Pacira Shares Look Expensive, Stifel Says In Bearish Initiation",2018-09-14 15:55:00-04:00,PCRX,positive
989850.0,"Benzinga's Top Upgrades, Downgrades For September 14, 2018",2018-09-14 09:25:00-04:00,PCRX,positive
989851.0,"Stifel Nicolaus Initiates Coverage On Pacira Pharmaceuticals with Sell Rating, Announces $41 Price Target",2018-09-14 07:06:00-04:00,PCRX,neutral
989852.0,"Stocks Which Set New 52-Week High Yesterday, August 16th",2018-08-17 10:39:00-04:00,PCRX,neutral
989853.0,"Stocks Which Set New 52-Week High Yesterday, August 15th",2018-08-16 10:22:00-04:00,PCRX,neutral
989854.0,"The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait",2018-08-16 09:37:00-04:00,PCRX,negative
989855.0,"Stocks Which Set New 52-Week High Yesterday, August 14th",2018-08-15 12:29:00-04:00,PCRX,neutral
989856.0,"Benzinga's Top Upgrades, Downgrades For August 6, 2018",2018-08-06 09:13:00-04:00,PCRX,positive
989857.0,"Barclays Maintains Overweight on Pacira Pharmaceuticals, Raises Price Target to $50",2018-08-06 08:21:00-04:00,PCRX,negative
989858.0,Bank of America Downgrades Pacira Pharmaceuticals to Neutral,2018-08-06 08:04:00-04:00,PCRX,neutral
989859.0,"Wedbush Maintains Outperform on Pacira Pharmaceuticals, Raises Price Target to $85",2018-08-06 08:02:00-04:00,PCRX,neutral
989860.0,"Benzinga's Top Upgrades, Downgrades For August 3, 2018",2018-08-03 09:41:00-04:00,PCRX,positive
989861.0,Needham Upgrades Pacira Pharmaceuticals to Buy,2018-08-03 07:39:00-04:00,PCRX,neutral
989862.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,PCRX,positive
989863.0,"Pacira Pharmaceuticals Q2 EPS $0.24 Beats $0.07 Estimate, Sales $84.1M Beat $78.86M Estimate",2018-08-02 08:46:00-04:00,PCRX,neutral
989864.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,PCRX,neutral
989865.0,"Pacira Reports Prelim. Net EXPAREL Sales of $80.4M for Q2, Up 15% YoY In Same Period",2018-07-10 07:31:00-04:00,PCRX,neutral
989866.0,56 Biggest Movers From Yesterday,2018-06-22 04:08:00-04:00,PCRX,neutral
989867.0,Pacira Pharmaceuticals Option Alert: Jul 20 $35 Puts at the Bid: 1000 @ $1.0 vs 2277 OI; Earnings 8/1 Before Open [est] Ref=$39.95,2018-06-20 11:31:00-04:00,PCRX,positive
989868.0,"Pacira Pharmaceuticals, Nuance Biotech Report License Agreement for EXPAREL in China; Pacira Grants Nuance Rights To Develop And Commercialize  EXPAREL In China For An Upfront Payment Of $3m And Is Eligible For Milestone Payments Of $55M",2018-06-19 07:33:00-04:00,PCRX,positive
989869.0,Pacira Pharmaceuticals Option Alert: Jul 20 $37.5 Calls at the Ask: 1500 @ $2.601 vs 157 OI; Earnings 8/1 Before Open [est] Ref=$37.2,2018-06-11 13:02:00-04:00,PCRX,positive
989870.0,"Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss",2018-05-03 08:31:00-04:00,PCRX,negative
989871.0,Pacira Pharmaceuticals Sees FY2018 EXPAREL Net Product Sales $300.0M-310.0M,2018-05-03 08:19:00-04:00,PCRX,neutral
989872.0,"Pacira Pharmaceuticals Q1 EPS $0.02 Beats $0.01 Estimate, Sales $74.607M Beat $73.93M Estimate",2018-05-03 08:18:00-04:00,PCRX,neutral
989873.0,Pacira On Friday Announced FDA Approval Of Supplemental New Drug Application For EXPAREL As Opioid-Free Nerve Block For Regional Analgesia,2018-04-09 09:10:00-04:00,PCRX,positive
989874.0,30 Biggest Movers From Friday,2018-04-09 04:23:00-04:00,PCRX,neutral
989875.0,"Pacira Shares Spike to $34.75, FDA.gov Site Shows Label Approval For EXPAREL",2018-04-06 13:10:00-04:00,PCRX,positive
989876.0,Pacira Pharma Shares Spike To High Of $31.50 on Volume,2018-04-06 13:06:00-04:00,PCRX,positive
989877.0,REMINDER: Pacira Pharma Has PDUFA Date Today For EXPAREL sNDA,2018-04-06 06:59:00-04:00,PCRX,neutral
989878.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2018-04-03 08:14:00-04:00,PCRX,neutral
989879.0,41 Biggest Movers From Yesterday,2018-04-03 04:18:00-04:00,PCRX,neutral
989880.0,"The Week Ahead: Switch's Lockup Expires, Spotify Debuts, And More",2018-04-02 15:35:00-04:00,PCRX,neutral
989881.0,"The Week Ahead In Biotech: PDUFA Dates, Clinical Trials And Conferences",2018-03-30 09:46:00-04:00,PCRX,neutral
989882.0,Pacira Sees FY18 EXPAREL Net Product Sales Of $300-$310M,2018-02-28 08:03:00-05:00,PCRX,neutral
989883.0,"Pacira Reports Q4 EPS $0.39 vs $0.10 Est., Sales $79.1M vs $79.3M Est.",2018-02-28 08:03:00-05:00,PCRX,neutral
989884.0,45 Biggest Movers From Friday,2018-02-20 04:50:00-05:00,PCRX,neutral
989885.0,"Pacira Pharma Shares Down ~17% After FDA AdCom Didn't Recommend Approval of EXPAREL Thursday, Needham Downgraded Stock To Hold Earlier",2018-02-16 14:23:00-05:00,PCRX,negative
989886.0,36 Stocks Moving In Friday's Mid-Day Session,2018-02-16 12:25:00-05:00,PCRX,neutral
989887.0,Needham Downgrades Pacira Pharmaceuticals to Hold,2018-02-16 08:45:00-05:00,PCRX,neutral
989888.0,32 Stocks Moving In Friday's Pre-Market Session,2018-02-16 08:05:00-05:00,PCRX,neutral
989889.0,"Pacira Pharma Shares Resume Trade, Down 16%",2018-02-15 16:18:00-05:00,PCRX,positive
989890.0,Pacira Pharmaceuticals To Resume Trade At 4:15pm,2018-02-15 15:50:00-05:00,PCRX,neutral
989891.0,"UPDATE: Pacira Says 4 Committee Members Voted To Recommend EXPAREL Approval, 6 Believes More Research Is Needed To Further Support New Indication",2018-02-15 15:36:00-05:00,PCRX,positive
989892.0,"Pacira Pharma Offers Statement On FDA Panel For EXPAREL: Says Did Not Reach Unanimous Decision On Efficacy, Safety",2018-02-15 15:35:00-05:00,PCRX,positive
989893.0,"REMINDER: Pacira Pharma Shares Remain Halted, As FDA AdCom Mtg. for EXPAREL Concludes Today",2018-02-15 08:46:00-05:00,PCRX,positive
989894.0,"Pacira Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review sNDA for EXPAREL as a Nerve Block for Regional Analgesia, Anesthetic and Analgesic Drug Products Advisory Committee Meeting February 14-15",2018-02-14 13:28:00-05:00,PCRX,negative
989895.0,Pacira Pharmaceuticals Halted News Pendings,2018-02-14 13:26:00-05:00,PCRX,neutral
989896.0,"The Week Ahead: Earnings, FDA Actions, And Industry Conferences To Watch",2018-02-12 14:06:00-05:00,PCRX,neutral
989897.0,"FDA Posts Briefing Documents for Advisory Meeting Reviewing sNDA for EXPAREL as a Nerve Block for Regional Analgesia, Adcom. meeting Scheduled For Feb. 14th-15th",2018-02-12 13:32:00-05:00,PCRX,negative
989898.0,Attention Biotech Investors: February PDUFA Catalysts Come Calling,2018-01-31 15:30:00-05:00,PCRX,neutral
989899.0,"Seaport Global Initiates Coverage On Pacira Pharmaceuticals with Buy Rating, Announces $50.00 Price Target",2018-01-19 10:10:00-05:00,PCRX,neutral
989900.0,Pacira Pharma Shares Down 7% Thurs. Following Earlier Q4 Guidance; Thurs. Morning Price Failed To Hold Over $46 For Third Time Since End Of Nov.,2018-01-04 13:49:00-05:00,PCRX,negative
989901.0,Pacira Pharma Reports Prelim. Total Sales Figures: Q4 $79.1M vs $78.6M Est.; FY17 $286.6M vs $286M Est.,2018-01-04 07:33:00-05:00,PCRX,neutral
989902.0,"Benzinga's Top Upgrades, Downgrades For January 3, 2018",2018-01-03 09:14:00-05:00,PCRX,positive
989903.0,"Leerink Swann Initiates Coverage On Pacira Pharmaceuticals with Market Perform Rating, Announces $46.00 Price Target",2018-01-03 08:40:00-05:00,PCRX,neutral
989904.0,"Benzinga's Top Upgrades, Downgrades For December 18, 2017",2017-12-18 09:16:00-05:00,PCRX,positive
989905.0,"JP Morgan Initiates Coverage On Pacira Pharmaceuticals with Neutral Rating, Announces $47.00 Price Target",2017-12-18 06:37:00-05:00,PCRX,positive
989906.0,"Pacira Names Dr. Scott Braunstein COO, Dr. Richard Scranton Chief Scientific Officer",2017-12-07 07:33:00-05:00,PCRX,neutral
989907.0,"Benzinga's Top Upgrades, Downgrades For November 29, 2017",2017-11-29 09:11:00-05:00,PCRX,positive
989908.0,Mizuho Downgrades Pacira Pharmaceuticals to Neutral,2017-11-29 07:14:00-05:00,PCRX,neutral
989909.0,Pacira's Exparel sNDA To Be Reviewed By FDA Advisory Committee,2017-11-15 12:48:00-05:00,PCRX,neutral
989910.0,Pacira Announces FDA Advisory Committee Meeting to Review sNDA for EXPAREL as a Nerve Block for Regional Analgesia,2017-11-14 07:37:00-05:00,PCRX,negative
989911.0,"Pacira Reports FDA Advisory Committee Meeting to Review sNDA for EXPAREL Tentatively Scheduled For Feb. 14-15, 2018",2017-11-14 07:32:00-05:00,PCRX,neutral
989912.0,"BMO Capital Maintains Market Perform on Pacira Pharmaceuticals, Raises Price Target to $39.00",2017-11-09 09:29:00-05:00,PCRX,neutral
989913.0,"H.C. Wainwright Assumes Pacira Pharmaceuticals at Buy, Announces price target $52.00",2017-11-09 07:47:00-05:00,PCRX,neutral
989914.0,57 Biggest Movers From Yesterday,2017-11-09 05:16:00-05:00,PCRX,neutral
989915.0,Pacira Pharmaceuticals Lowers FY17 EXPAREL Net Product SalesFrom $290-$310M To $280-$285M,2017-11-08 07:38:00-05:00,PCRX,negative
989916.0,"Pacira Pharmaceuticals Reports Q3 EPS $0.11 vs $(0.06) Est., Sales $67.3M vs $70M Est.",2017-11-08 07:37:00-05:00,PCRX,neutral
989917.0,"Benzinga's Top Upgrades, Downgrades For October 30, 2017",2017-10-30 09:22:00-04:00,PCRX,positive
989918.0,Canaccord Genuity Downgrades Pacira Pharmaceuticals to Hold,2017-10-30 06:45:00-04:00,PCRX,neutral
989919.0,22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency,2017-10-26 15:24:00-04:00,PCRX,negative
989920.0,Pres Trump Implies Top Priority Is Removing Fentanyl From Market,2017-10-26 14:37:00-04:00,PCRX,positive
989921.0,Watching Opioid-Related Stocks As Pres Trump Declares America's Opioid Epidemic A National Public Health Emergency,2017-10-26 14:33:00-04:00,PCRX,negative
989922.0,"Benzinga's Top Upgrades, Downgrades For October 26, 2017",2017-10-26 09:13:00-04:00,PCRX,positive
989923.0,"The Market In 5 Minutes: Twitter Beats Estimates, WSJ Goes After Morningstar's Rating System",2017-10-26 09:01:00-04:00,PCRX,neutral
989924.0,Janney Capital Downgrades Pacira Pharmaceuticals to Sell,2017-10-26 06:42:00-04:00,PCRX,neutral
989925.0,Pacira Pharma Announces up to a $25M Investment in TELA Bio,2017-10-25 08:07:00-04:00,PCRX,neutral
989926.0,Pacira Pharma Reports FDA Acceptance Of sNDA For EXPAREL As Nerve Block To Produce Regional Analgesia,2017-10-18 07:32:00-04:00,PCRX,neutral
989927.0,Watch These 7 Huge Call Purchases In Thursday Trade,2017-10-12 04:00:00-04:00,PCRX,positive
989928.0,Benzinga's Option Alert Recap From October 11,2017-10-11 16:15:00-04:00,PCRX,positive
989929.0,Pacira Pharma Option Alert: Nov 17 $35 Calls Sweep (25) at the Bid: 521 @ $2.4 vs 231 OI; Ref=$34.375,2017-10-11 15:58:00-04:00,PCRX,positive
989930.0,"Goldman Sachs Initiates Coverage On Pacira Pharmaceuticals with Neutral Rating, Announces $41.00 Price Target",2017-09-28 07:53:00-04:00,PCRX,neutral
989931.0,Benzinga's Option Alert Recap From September 19,2017-09-19 16:30:00-04:00,PCRX,positive
989932.0,Pacira Pharma Option Alert: Nov 17 $40 Calls at the Ask: 500 @ $1.9 vs 97 OI; Ref=$35.85,2017-09-19 13:27:00-04:00,PCRX,positive
989933.0,Oppenheimer Initiates Coverage On Pacira Pharmaceuticals with Market Perform Rating,2017-09-07 07:59:00-04:00,PCRX,neutral
989934.0,Watch These 3 Huge Call Purchases In Wednesday Trade,2017-09-06 04:13:00-04:00,PCRX,positive
989935.0,Benzinga's Option Alert Recap From September 5,2017-09-05 16:21:00-04:00,PCRX,positive
989936.0,Pacira Pharma Option Alert: Nov 17 $45 Calls at the Ask: 1300 @ $1.5 vs 37 OI; Ref=$37.25 Signals 11:44:22am,2017-09-05 11:46:00-04:00,PCRX,positive
989937.0,13G Filing From Point72 Shows 5% Stake In Pacira Pharmaceuticals,2017-08-22 16:11:00-04:00,PCRX,neutral
989938.0,"Needham Initiates Coverage On Pacira Pharmaceuticals with Buy Rating, Announces $55.00 Price Target",2017-08-22 08:49:00-04:00,PCRX,neutral
989939.0,"Benzinga's Top Upgrades, Downgrades For August 21, 2017",2017-08-21 09:29:00-04:00,PCRX,positive
989940.0,Janney Capital Upgrades Pacira Pharmaceuticals to Neutral,2017-08-21 07:09:00-04:00,PCRX,neutral
989941.0,Healthcor Management Reports 6.2% Passive Stake In Pacira Pharmaceuticals -13G,2017-08-14 06:12:00-04:00,PCRX,positive
989942.0,Pacira Pharmaceuticals Sees FY17 Sales $290-$310M vs $304M Est.,2017-08-02 07:38:00-04:00,PCRX,neutral
989943.0,"Pacira Pharmaceuticals Reports Q2 Adj. EPS $(0.11) vs $(0.03) Est., Sales $70.9M vs $73.6M Est.",2017-08-02 07:38:00-04:00,PCRX,neutral
989944.0,"Pacira Reports Publication of Phase 4 Study of EXPAREL in Patients Undergoing Total Knee Replacement in The Journal of Arthroplasty, Showed 78% Decrease In Opioid Consumption And Better Pain Control With Infiltration of EXPAREL Plus bupivacaine vs bupiva",2017-07-26 07:38:00-04:00,PCRX,negative
989945.0,Mid-Afternoon Market Update: Crude Oil Up 3%; Seagate Shares Drop After Q4 Miss,2017-07-25 14:51:00-04:00,PCRX,negative
989946.0,20 Biggest Mid-Day Losers For Tuesday,2017-07-25 12:50:00-04:00,PCRX,negative
989947.0,Mid-Day Market Update: Dow Rises Over 100 Points; Team Shares Plummet,2017-07-25 12:05:00-04:00,PCRX,positive
989948.0,Pacira Pharma Shares Down 8.4% Pre-Market Following Disappointing Lower Extremity Study Results From Phase 3 Study Of EXPAREL,2017-07-25 09:19:00-04:00,PCRX,negative
989949.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-07-25 08:24:00-04:00,PCRX,neutral
989950.0,"Pacira Phase 3 Results For EXPAREL Demonstrated Statistical Significance For Both Primary And Secondary Endpoints In Upper Extremity Study But Did Not For The Lower Extremity Study, Timing For Resubmission Of Supplemental NDA Remains On Track",2017-07-25 07:38:00-04:00,PCRX,positive
989951.0,8-K From Pacira Pharma Shows Company To Discontinue All Production Of DepoCyt Due To 'Persistent Technical Issues' Specific To The Manufacturing Process,2017-06-29 16:41:00-04:00,PCRX,neutral
989953.0,Pacira Pharma Announces Pres James Scibetta Resigned; Says Does Not Intend to Name Successor,2017-05-23 16:31:00-04:00,PCRX,neutral
989954.0,"Pacira Pharmaceuticals Reports Q1 EPS $0.15 vs $(0.04) Est., Sales $69.3M vs $70.2M Est.",2017-05-04 08:22:00-04:00,PCRX,neutral
989955.0,Partner Fund Management Reports 5.9% Stake in Pacira Pharmaceuticals in 13G,2017-04-17 06:33:00-04:00,PCRX,neutral
989956.0,"RBC Capital Initiates Coverage On Pacira Pharmaceuticals with Outperform Rating, Announces $58.00 Price Target",2017-04-13 06:24:00-04:00,PCRX,neutral
989957.0,"Trinity Health, Pacira Pharmaceuticals Announce Collaboration to Decrease Opioid Use",2017-03-23 04:01:00-04:00,PCRX,neutral
989958.0,"Wedbush Reiterates Outperform On Pacira Pharmaceuticals, Maintains $89 Price Target",2017-03-22 06:31:00-04:00,PCRX,neutral
989959.0,Leerink Presents: Your 2017 Biopharma Catalyst Tracker,2017-03-20 09:17:00-04:00,PCRX,neutral
989960.0,Pacira Pharmaceuticals Reports Co-Primary Endpoints Met Statistical Significance,2017-03-14 07:31:00-04:00,PCRX,positive
989961.0,20 Biggest Mid-Day Gainers For Wednesday,2017-03-01 12:46:00-05:00,PCRX,neutral
989962.0,"Pacira Pharmaceuticals Reports Q4 EPS $0.10 vs. $0.01 Est., $72.9M vs. $73M Est.",2017-03-01 07:43:00-05:00,PCRX,neutral
989963.0,"Pacira Pharma Reports Q4 Adj. EPS $0.09 vs $0.01 Est., Sales $72.9M vs $73M Est.",2017-03-01 07:34:00-05:00,PCRX,neutral
989964.0,Canaccord Genuity Initiates Coverage On Pacira Pharmaceuticals to Buy,2017-02-22 06:41:00-05:00,PCRX,neutral
989965.0,Your Guide To 2017's Emerging Pharmaceuticals Catalysts,2017-02-07 14:39:00-05:00,PCRX,neutral
989966.0,Hearing Cowen Out Cautious On Pacira Pharmaceuticals,2017-01-25 14:25:00-05:00,PCRX,negative
989967.0,"Pacira Pharma Reports Collaboration with DePuy Synthes for Suppporting of Promotion, Education, Training of EXPAREL in Orthopedics",2017-01-25 07:30:00-05:00,PCRX,neutral
989968.0,Mid-Afternoon Market Update: AZZ Drops On Weak Q3 Results; Stemline Shares Spike Higher,2017-01-06 14:22:00-05:00,PCRX,negative
989969.0,15 Biggest Mid-Day Gainers For Friday,2017-01-06 12:51:00-05:00,PCRX,neutral
989970.0,Mid-Day Market Update: Dow Gains 50 Points; Ruby Tuesday Shares Fall Following Q2 Results,2017-01-06 12:00:00-05:00,PCRX,positive
989971.0,Pacira Pharma Q4 Revenue $72.9M vs $72.6M Est,2017-01-06 07:37:00-05:00,PCRX,neutral
989972.0,13 Emerging Biotechs With Catalysts In 2017,2017-01-03 14:22:00-05:00,PCRX,neutral
989973.0,"Benzinga's Top Upgrades, Downgrades For January 3, 2017",2017-01-03 09:20:00-05:00,PCRX,positive
989974.0,"H.C. Wainwright Initiates Coverage On Pacira Pharmaceuticals at Buy, Announces price target $43.00",2017-01-03 08:18:00-05:00,PCRX,neutral
989975.0,Benzinga's Top Initiations,2016-12-02 09:24:00-05:00,PCRX,positive
989976.0,"Janney Capital Initiates Coverage On Pacira Pharmaceuticals at Neutral, Announces $31.00 Target",2016-12-02 06:44:00-05:00,PCRX,neutral
989977.0,"Goldman Sachs Initiates Coverage On Pacira Pharmaceuticals at Neutral, Announces $36.00 Target",2016-12-01 05:28:00-05:00,PCRX,neutral
989978.0,"Pacira Pharmaceuticals, GeneAlign Report Partnership to Develop Low-Opioid Pain Management Protocols for Postsurgical Patients at High Risk of Addiction",2016-11-29 07:33:00-05:00,PCRX,negative
989979.0,Jefferies London Health Care Conference Continues Today,2016-11-17 10:14:00-05:00,PCRX,positive
989980.0,Pacira Sees FY16 Rev. $263-$268M vs. Est. $277M,2016-11-02 07:40:00-04:00,PCRX,neutral
989981.0,"Pacira Pharmaceuticals Reports Q3 EPS $0.22 vs. Est. $(0.02), Rev. $68.4M vs. Est. $67M",2016-11-02 07:39:00-04:00,PCRX,neutral
989982.0,Benzinga's Top Upgrades,2016-10-27 08:50:00-04:00,PCRX,positive
989983.0,"BMO Capital Upgrades Pacira Pharmaceuticals, Inc. - Common Stock to Market Perform, Lowers to $35.00",2016-10-27 05:55:00-04:00,PCRX,negative
989984.0,Brean Capital Assumes Pacira Pharmaceuticals at Hold,2016-10-07 06:59:00-04:00,PCRX,neutral
989985.0,Mid-Afternoon Market Update: Dow Surges 125 Points; FedEx Shares Jump Following Upbeat Earnings,2016-09-21 15:26:00-04:00,PCRX,positive
989986.0,12 Biggest Mid-Day Losers For Wednesday,2016-09-21 13:03:00-04:00,PCRX,negative
989987.0,Mid-Day Market Update: Crude Oil Up 2.75%; Mast Therapeutics Shares Drop After Sickle Cell Drug Phase 3 Trial Fail,2016-09-21 12:16:00-04:00,PCRX,negative
989988.0,"Pacira Pharma Reports Launch of EXPAREL for Treatment of Pain Following Oral, Maxilofacial Procedures",2016-09-21 12:00:00-04:00,PCRX,negative
989989.0,Mid-Morning Market Update: Markets Open Higher; General Mills Earnings Top Views,2016-09-21 10:05:00-04:00,PCRX,positive
989990.0,Benzinga's Top Initiations,2016-09-07 09:29:00-04:00,PCRX,positive
989991.0,Cowen & Company Initiates Coverage on Pacira Pharmaceuticals at Market Perform,2016-09-07 06:38:00-04:00,PCRX,neutral
989992.0,Major Averages Close Thursday's Session Mostly Unchanged,2016-08-04 16:52:00-04:00,PCRX,neutral
989993.0,20 Biggest Mid-Day Gainers For Thursday,2016-08-04 12:49:00-04:00,PCRX,neutral
989994.0,Pacira Sees FY16 EXPAREL Product Sales $270M-$280M vs $282.5M Est.,2016-08-04 07:55:00-04:00,PCRX,neutral
989995.0,"Pacira Pharma Reports Q2 Adj. EPS $0.19 vs $0.23 in Same Qtr. Last Year, Sales $65.8M vs $67.4M Est.",2016-08-04 07:55:00-04:00,PCRX,neutral
989996.0,Benzinga's Volume Movers,2016-07-01 11:02:00-04:00,PCRX,neutral
989997.0,"Exparel Concerns Weigh On Pacira Pharma, Brean Moves To Sidelines",2016-07-01 09:20:00-04:00,PCRX,neutral
989998.0,"Pacira Pharmaceuticals To Terminate Agreement With CrossLink, Will Incur Termination Fee Of $7.3M",2016-07-01 07:42:00-04:00,PCRX,positive
989999.0,Brean Capital Downgrades Pacira Pharmaceuticals to Hold,2016-07-01 05:08:00-04:00,PCRX,neutral
990000.0,Pacira Pharmaceuticals Sells off to Low of $32.71 on Vol,2016-06-30 15:36:00-04:00,PCRX,negative
990001.0,Pacira Shares Tumble Following BMO's New Underperform Rating,2016-06-29 16:00:00-04:00,PCRX,positive
990002.0,BMO Capital Initiates Coverage on Pacira Pharmaceuticals at Underperform,2016-06-29 06:26:00-04:00,PCRX,neutral
990003.0,"Pacira Pharma Reports Q1 Adj. EPS $0.15 vs $0.08 Est., Sales $63.8M vs $67M Est.",2016-05-02 07:33:00-04:00,PCRX,neutral
990004.0,"Mizuho: Pacira Pharma Has 'Forever' Potential, Stock Is A Buy",2016-04-19 10:16:00-04:00,PCRX,neutral
990005.0,Pacira Pharma Names Charles Reinhart CFO,2016-04-19 08:05:00-04:00,PCRX,neutral
990006.0,Mizuho Securities Initiates Coverage on Pacira Pharmaceuticals at Buy,2016-04-19 07:12:00-04:00,PCRX,positive
990007.0,Option Alert: PCRX Aug16 75.0 Puts Sweep: 550 @  ASK  $14.70: 556 traded vs 256 OI:  Earnings 5/2 Before Open  $64.86 Ref,2016-04-18 09:57:00-04:00,PCRX,positive
990008.0,Pacira Pharmaceuticals Names Robert Weiland as Chief Commercial Officer,2016-04-05 07:30:00-04:00,PCRX,neutral
990009.0,"Brean Capital Maintains Buy on Pacira Pharmaceuticals, Lowers PT to $75.00",2016-02-26 05:48:00-05:00,PCRX,negative
990010.0,"Pacira Pharmaceuticals Reports Q4 EPS $0.22 vs. Est. $0.27, Rev. $69.3M vs. Est. $68.4M",2016-02-25 07:36:00-05:00,PCRX,neutral
990011.0,Pacira Pharma Shares Spike to High of $60; May be Attributed to BofA Upgrade,2016-01-29 15:16:00-05:00,PCRX,positive
990012.0,Mid-Afternoon Market Update: Dow Rises Over 100 Points; eBay Shares Drop On Disappointing Outlook,2016-01-28 14:31:00-05:00,PCRX,negative
990013.0,"Pacira Pharma Sees Q4 Total Sales $69.4M vs $67.44M Est., FY15 Total Sales $249M vs $247M Est.",2016-01-07 07:35:00-05:00,PCRX,neutral
990014.0,Benzinga's Top Initiations,2016-01-05 09:54:00-05:00,PCRX,positive
990015.0,"CORRECTION: JMP Securities Initiates Coverage on Pacira Pharmaceuticals at Market Outperform, Announces $92.00 PT",2016-01-05 08:25:00-05:00,PCRX,positive
990016.0,"JMP Securities Initiates Coverage on Pacira Pharmaceuticals at Market Outperform, Announces $92.00 PT",2016-01-05 08:25:00-05:00,PCRX,positive
990017.0,Every Biotech Catalyst Wedbush Is Watching In 2016,2016-01-02 20:20:00-05:00,PCRX,neutral
990018.0,Mid-Day Market Update: Kennametal Drops On Lowered Guidance; Lumber Liquidators Shares Jump,2015-12-15 13:30:00-05:00,PCRX,positive
990019.0,Benzinga's Volume Movers,2015-12-15 10:19:00-05:00,PCRX,neutral
990020.0,Mid-Morning Market Update: Markets Open Higher; FactSet Misses Q1 Views,2015-12-15 10:04:00-05:00,PCRX,negative
990021.0,Pacira Pharmaceuticals Achieves Favorable Resolution With FDA; Reaffirms Broad Indication for EXPAREL,2015-12-15 04:13:00-05:00,PCRX,positive
990022.0,Mid-Morning Market Update: Markets Edge Higher; Deere Profit Tops Views,2015-11-25 10:16:00-05:00,PCRX,positive
990023.0,Mid-Afternoon Market Update: GrubHub Drops On Earnings Miss; Pacira Pharmaceuticals Shares Gain,2015-10-27 15:43:00-04:00,PCRX,positive
990024.0,Mid-Day Market Update: Heidrick & Struggles Jumps On Strong Results; Roadrunner Transportation Systems Shares Decline,2015-10-27 13:18:00-04:00,PCRX,positive
990025.0,Mid-Morning Market Update: Markets Down; Ford Earnings Miss Views,2015-10-27 10:27:00-04:00,PCRX,negative
990026.0,Morning Market Gainers,2015-10-27 09:54:00-04:00,PCRX,neutral
990027.0,Benzinga's Top #PreMarket Gainers,2015-10-27 09:15:00-04:00,PCRX,positive
990028.0,"Pacira Pharma Reports Q3 Sales $62.2M vs $60M Est., Adj. EPS $0.32 vs $0.15 Est.",2015-10-27 07:39:00-04:00,PCRX,neutral
990029.0,"Biotech Names Like Horizon, Pacira, Akorn, Shire, Mallinckrodt  Volatile On Citron Report & Subsequent Valeant Pharma. Press Release",2015-10-21 14:14:00-04:00,PCRX,positive
990030.0,Pacira Pharmaceuticals Names James S. Scibetta as President,2015-10-20 07:34:00-04:00,PCRX,neutral
990031.0,Shares of Pacira Pharma Up ~8%; Hearing Law360 Reporting FDA Has Removed Warning Letter Related to Facility,2015-10-19 10:30:00-04:00,PCRX,negative
990032.0,5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm,2015-09-29 15:27:00-04:00,PCRX,neutral
990033.0,"Nomura Lists AGN, VRX, PCRX, ENDP, & PDHL As Top Picks, Says M&A Remains Value Driver & More Consolidation",2015-09-29 06:28:00-04:00,PCRX,positive
990034.0,Wedbush Thinks Pacira Pharma Is Worth $106 On Exparel Sales,2015-09-23 14:02:00-04:00,PCRX,positive
990035.0,Morning Market Losers,2015-09-23 09:57:00-04:00,PCRX,negative
990036.0,Pacira Pharmaceuticals Seeks Court Injunction to Defend its Rights to Share Information about EXPAREL Consistent with its FDA-Approved Indication,2015-09-08 16:50:00-04:00,PCRX,positive
990037.0,"Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, as SVP and Chief Medical Officer",2015-08-19 07:33:00-04:00,PCRX,neutral
990038.0,Bank of America Upgrades Pacira Pharmaceuticals to Neutral,2015-07-31 09:45:00-04:00,PCRX,neutral
990039.0,"Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results for Controlling Postsurgical Pain in Dogs",2015-07-15 08:01:00-04:00,PCRX,positive
990040.0,Aratana Therapeutics Announces Positive Pivotal Results for AT-003,2015-07-14 16:07:00-04:00,PCRX,positive
990041.0,Leerink Swann Initiates Pacira Pharmaceuticals With Market Perform,2015-06-19 09:53:00-04:00,PCRX,neutral
990042.0,Benzinga's Top Initiations,2015-06-19 09:23:00-04:00,PCRX,positive
990043.0,"Leerink Swann Initiates Coverage on Pacira Pharmaceuticals at Market Perform, Announces $86.00 PT",2015-06-19 07:50:00-04:00,PCRX,neutral
990044.0,Who's The Next Big Pharma Acquisition?,2015-05-29 11:20:00-04:00,PCRX,neutral
990045.0,Pacira Pharmaceuticals Announces Completion of End-of-Review Process with FDA Regarding EXPAREL sNDA for Nerve Block,2015-05-28 06:31:00-04:00,PCRX,negative
990046.0,Pacira Announces New Data Supporting Clinical and Pharmacoeconomic Utility of EXPAREL in Patients Undergoing Various Surgical Procedures,2015-05-19 16:31:00-04:00,PCRX,positive
990047.0,Morning Market Losers,2015-04-30 10:10:00-04:00,PCRX,negative
990048.0,"Pacira Pharma Q1 EPS $0.23 vs $0.20 est, Revenue $58.3M vs $61.1M est",2015-04-30 06:33:00-04:00,PCRX,neutral
990049.0,Morning Market Losers,2015-04-16 10:04:00-04:00,PCRX,negative
990050.0,Benzinga's Top #PreMarket Losers,2015-04-16 08:28:00-04:00,PCRX,negative
990051.0,Pacira Receives Subpoena from US DoJ,2015-04-16 06:43:00-04:00,PCRX,neutral
990052.0,Pacira Reports New Data on Health Economic Benefits of EXPAREL for Post Surgery Pain Control Proceeding Complete Knee Replacement Surgery,2015-04-10 07:16:00-04:00,PCRX,negative
990053.0,Pacira Says Data Reinforce Benefits of EXPAREL for Postsurgical Pain Control,2015-03-26 06:31:00-04:00,PCRX,negative
990054.0,Pacira Announces Data Reinforcing Benefits of EXPAREL for Postsurgical Pain Control Following Total Hip and Knee Replacement Surgery,2015-03-26 06:31:00-04:00,PCRX,negative
990055.0,Wedbush Securities Believes SH Data Bodes Well For Pacira Pharmaceuticals,2015-03-25 10:14:00-04:00,PCRX,positive
990056.0,Morning Market Losers,2015-03-02 09:55:00-05:00,PCRX,negative
990057.0,Pacira Pharmaceuticals Shares Fall 14% Premarket on CRL from FDA for EXPAREL sNDA,2015-03-02 08:24:00-05:00,PCRX,positive
990058.0,Benzinga's Top #PreMarket Losers,2015-03-02 08:19:00-05:00,PCRX,negative
990059.0,Pacira Receives CRL from FDA for sNDA Seeking Approval of EXPAREL Use in Nerve Block to Provide Postsurgical Analgesia,2015-03-02 06:33:00-05:00,PCRX,positive
990060.0,Bank of America Downgrades Pacira Pharmaceuticals to Underperform,2015-02-26 07:40:00-05:00,PCRX,neutral
990061.0,JPM Securities Picks Through Biotech News For Winners,2015-02-25 12:41:00-05:00,PCRX,positive
990062.0,"Pacira Pharma Q4 EPS $0.35 vs $0.27, Revenue $61.8M vs $62.1M",2015-02-24 06:31:00-05:00,PCRX,neutral
990063.0,3 Niche ETFs Breaking Out,2015-02-17 14:42:00-05:00,PCRX,neutral
990064.0,US Stock Futures Edge Lower Ahead Of Earnings,2015-02-11 07:26:00-05:00,PCRX,negative
990065.0,Pacira Pharmaceuticals Announces Resolution of Warning Letter with FDA's OPDP,2015-02-11 06:32:00-05:00,PCRX,negative
990066.0,Biotech Breakout Alert: Pacira Pharmaceuticals Could Be On The Cusp,2015-02-04 13:20:00-05:00,PCRX,positive
990067.0,"Biotech Breakdown: Market Breaks...Gilead, Kite Pharma & Biogen Idec Worth Watching",2015-02-01 21:14:00-05:00,PCRX,positive
990068.0,Pacira Preliminary Q4 Revenue $81.8M vs $60.44M,2015-01-08 06:32:00-05:00,PCRX,neutral
990069.0,New Biotech ETF From ALPS,2015-01-02 08:05:00-05:00,PCRX,neutral
990070.0,Aratana Therapeutics Initiates Pivotal Study For AT-003,2014-12-16 16:29:00-05:00,PCRX,neutral
990071.0,"Pacira Pharma Reports Changes to EXPAREL Label, Indication Not Affected",2014-12-12 08:33:00-05:00,PCRX,positive
990072.0,Pacira Pharmaceuticals Inc. Announces New Data on the Use of EXPAREL to Treat Postsurgical Pain Following Total Knee Arthroplasty ,2014-11-06 16:08:00-05:00,PCRX,negative
990073.0,"Bank of America Downgrades Pacira Pharmaceuticals, Inc. to Neutral",2014-10-31 09:20:00-04:00,PCRX,neutral
990074.0,"Pacira Pharmaceuticals, Inc. Reports Q3 EPS of $0.14 vs $0.10 Est; Revenue of $52.0M vs $52.20M Est",2014-10-30 06:36:00-04:00,PCRX,neutral
990075.0,New Study Correlates Use Of EXPAREL For Postsurgical Pain Management With Significant Reductions In Opioid Related Adverse Events ,2014-10-27 16:13:00-04:00,PCRX,negative
990076.0,Bank Of America Q3 Small & Mid-Cap Biotech Preview,2014-10-20 16:58:00-04:00,PCRX,neutral
990077.0,"Michael Boyd Of The Boyd Group On CNBC Speaking On Ebola Impact To Airliners Says ""This Is A Scare That WIll Evaporate""",2014-10-15 12:52:00-04:00,PCRX,negative
990078.0,"UPDATE: Pacira Pharma Sets Target PDUFA Date for EXPAREL as Mar. 5, 2015",2014-10-13 16:04:00-04:00,PCRX,neutral
990079.0,Pacira Pharma Offers Added Data Support Safety of EXPAREL in Peripheral Nerve Block,2014-10-13 16:00:00-04:00,PCRX,positive
990080.0,Bank Of America Sees Significant Manufacturing Capacity Expansions Underway For Pacira Pharmaceuticals,2014-10-08 11:13:00-04:00,PCRX,positive
990081.0,NASDAQ Dips 1.5%; HB Fuller Shares Decline On Downbeat Results,2014-09-25 12:09:00-04:00,PCRX,positive
990082.0,Markets Tumble; Scholastic Posts Wider Fiscal-First Quarter Loss,2014-09-25 11:12:00-04:00,PCRX,negative
990083.0,Morning Market Losers ,2014-09-25 09:44:00-04:00,PCRX,negative
990084.0,Benzinga's Top #PreMarket Losers,2014-09-25 08:11:00-04:00,PCRX,negative
990085.0,"US Stock Futures Flat Ahead Of Jobless Claims, Durable-Goods Orders Data",2014-09-25 07:35:00-04:00,PCRX,neutral
990086.0,"Pacira Pharmaceuticals, Inc. Announces Receipt of FDA Warning Letter",2014-09-25 06:59:00-04:00,PCRX,negative
990087.0,"Pacira Pharmaceuticals, Inc. Reports Q2 EPS of $0.04 vs $(0.20) Est; Revenue of $47.20M vs $43.17M Est",2014-07-31 06:37:00-04:00,PCRX,neutral
990088.0,UPDATE: Bank Of America Reiterates On Pacira Pharmaceuticals On Positive Survey Results,2014-07-17 08:33:00-04:00,PCRX,positive
990089.0,"Canaccord Genuity Initiates Coverage on Pacira Pharmaceuticals, Inc. at Buy, Announces $109.00 PT",2014-06-27 06:54:00-04:00,PCRX,neutral
990090.0,Pacira Pharmaceuticals Says Multi-Study Analysis Published in Journal of Pain Research Reinforces Value of Exparel-Based Regimen,2014-06-26 06:33:00-04:00,PCRX,negative
990091.0,3 Hot Biotech Stocks Hitting Highs,2014-06-23 14:00:00-04:00,PCRX,neutral
990092.0,UPDATE: JMP Securities Initiates Coverage On Pacira Pharmaceuticals,2014-06-17 10:43:00-04:00,PCRX,positive
990093.0,"JMP Securities Initiates Coverage on Pacira Pharmaceuticals, Inc. at Market Outperform",2014-06-17 06:30:00-04:00,PCRX,positive
990094.0,"Goldman Sachs Initiates Coverage on Pacira Pharmaceuticals, Inc. at Buy, Announces $93.00 PT",2014-06-02 06:32:00-04:00,PCRX,neutral
990095.0,Pacira Pharmaceuticals Submits sNDA to FDA for EXPAREL Nerve Block Indication ,2014-05-07 06:32:00-04:00,PCRX,negative
990096.0,Sohn Conference Moves Markets Once Again,2014-05-06 16:56:00-04:00,PCRX,neutral
990097.0,Gordon: PT on PCRX is $140,2014-05-05 17:04:00-04:00,PCRX,neutral
990098.0,Gordon: Likes Pacira Pharma,2014-05-05 17:01:00-04:00,PCRX,positive
990099.0,Pacira Pharmaceuticals Reports Q1 EPS of $(0.34) vs $(0.32) Est; Revenue of $36.70M vs $35.40M Est,2014-05-01 06:32:00-04:00,PCRX,neutral
990100.0,"Jefferies Initiates Coverage on Pacira Pharmaceuticals, Inc. at Buy, Announces $81.00 PT",2014-04-21 16:26:00-04:00,PCRX,neutral
990101.0,Pacira Pharma Reports Grants of Inducement Stock Options Related to NASDAQ Listing Rule 5635(c)(4),2014-04-15 16:41:00-04:00,PCRX,positive
990102.0,Benzinga's Volume Movers ,2014-04-09 10:22:00-04:00,PCRX,neutral
990103.0,Pacira Pharmaceuticals Prices 1.6M Share Offering at $64.00/Share,2014-04-08 20:12:00-04:00,PCRX,positive
990104.0,Pacira Pharma Announces $100M Offering of Common Stock,2014-04-07 16:35:00-04:00,PCRX,neutral
990105.0,Pacira Pharma Files Automatic Mixed Securities Shelf,2014-04-07 16:07:00-04:00,PCRX,positive
990106.0,CorMedix Welcomes Additional Board Members,2014-04-07 08:33:00-04:00,PCRX,positive
990107.0,Mid-Morning Market Update: Markets Open Higher; UTi Worldwide Reports Q4 Loss,2014-03-31 10:35:00-04:00,PCRX,negative
990108.0,Pacira Pharmaceuticals Announces FDA Approves Additional Manufacturing Suite for EXPAREL ,2014-03-31 06:42:00-04:00,PCRX,positive
990109.0,"Pacira Says Exparel Multimodal Analgesia Reduced Opioid Use, Says Data Reinforces Findings from IMPROVE Trial ",2014-01-07 16:32:00-05:00,PCRX,positive
990110.0,"Pacira Pharma Submits Prior Approval Supplement for Additional EXPAREL Manufacturing Suite, Expecting PDUFA Date in Early April 2014",2013-12-05 16:32:00-05:00,PCRX,positive
990111.0,"Shares of Pacira Pharma Breaking Out Over Resistance Level at $49, Charged Through $50, $51 Levels, Now Up 6+%; Jefferies Earlier Raised Price Target from $44 to $58",2013-10-01 10:49:00-04:00,PCRX,positive
990112.0,"Jefferies Maintains Buy on Pacira Pharmaceuticals, Inc., Raises PT to $58.00",2013-10-01 07:33:00-04:00,PCRX,neutral
990113.0,"Barclays Maintains Overweight on Pacira Pharmaceuticals, Inc., Raises PT to $43.00",2013-09-20 10:21:00-04:00,PCRX,negative
990114.0,UPDATE: Piper Jaffray Downgrades Pacira Pharmaceuticals Following 2Q13 Net Loss,2013-08-07 08:18:00-04:00,PCRX,negative
990115.0,"Piper Jaffray Downgrades Pacira Pharmaceuticals, Inc. to Neutral, Raises PT to $38.00",2013-08-06 16:44:00-04:00,PCRX,neutral
990116.0,Pacira Pharma Shares Sink as Co. Announces EXPAREL Phase 3 Trial Does Not Meet Primary Endpoint,2013-08-01 17:36:00-04:00,PCRX,positive
990117.0,"New Study Shows Significant Reduction in Opioids, Length of Hospital Stay and Cost of Care for Patients Receiving EXPAREL® Made By Pacira",2013-07-18 08:45:00-04:00,PCRX,positive
990118.0,"Stocks to Watch for July 01, 2013",2013-07-01 12:52:00-04:00,PCRX,neutral
990119.0,Pacira Pharmaceutical's EXPAREL Shows Positive Safety and Efficacy Results,2013-05-29 06:43:00-04:00,PCRX,positive
990120.0,"Pacira Pharmaceuticals, Inc. Reports Q1 EPS of $(0.71) vs $(0.41) Est; Revenue of $11.60M vs $13.22M Est",2013-05-08 06:36:00-04:00,PCRX,neutral
990121.0,Two New Studies Support Use of EXPAREL via Infiltration Into the Transversus Abdominis Plane for Postsurgical Pain Control ,2013-05-06 16:01:00-04:00,PCRX,negative
990122.0,MPM Bioventures IV Cuts Stake in Pacira Pharma from 10.1% Stake to 4.2%,2013-03-21 16:27:00-04:00,PCRX,negative
990123.0,"Mid-Day Market Update: Markets Trim Losses, Incyte Drops",2013-03-18 12:44:00-04:00,PCRX,negative
990124.0,"Pacira Pharmaceuticals Moves Lower, May be Attributed to Seeking Alpha Article",2013-03-13 09:32:00-04:00,PCRX,negative
990125.0,UPDATE: Jefferies Raises PT to $32 on Pacira Pharmaceuticals on Exparel Launch Momentum,2013-03-11 11:09:00-04:00,PCRX,neutral
990126.0,"Jefferies Maintains Buy on Pacira Pharmaceuticals, Inc., Raises PT to $32.00",2013-03-11 07:10:00-04:00,PCRX,neutral
990127.0,"UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Pacira Pharmaceuticals on Strong Momentum",2013-03-08 14:11:00-05:00,PCRX,positive
990128.0,UPDATE: Wedbush Raises PT to $32 on Pacira Pharmaceuticals on Long-Term Outlook,2013-03-07 13:41:00-05:00,PCRX,neutral
990129.0,"Wedbush Maintains Outperform on Pacira Pharmaceuticals, Inc., Raises PT to $32.00",2013-03-07 12:32:00-05:00,PCRX,neutral
990130.0,"Pacira Pharmaceuticals, Inc. Reports Q4 EPS of $(0.50) vs $(0.42) Est; Revenue of $10.45M vs $9.83M Est",2013-03-07 06:44:00-05:00,PCRX,neutral
990131.0,NASDAQ to Cancel Trades in Pacira Pharma Between 2:38-2:39PM EST,2013-02-01 16:21:00-05:00,PCRX,negative
990132.0,UPDATE: Piper Jaffray Raises PT to $27 on Pacira Pharmaceuticals on Strong Exparel Data Points,2013-01-28 13:59:00-05:00,PCRX,positive
990133.0,"Piper Jaffray Maintains Overweight on Pacira Pharmaceuticals, Inc., Raises PT to $27.00",2013-01-28 11:06:00-05:00,PCRX,negative
990134.0,"UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Pacira Pharmaceuticals",2013-01-18 10:52:00-05:00,PCRX,neutral
990135.0,"Jefferies Maintains Buy on Pacira Pharmaceuticals, Inc., Raises PT to $24.00",2013-01-18 07:39:00-05:00,PCRX,neutral
990136.0,Pacira Pharma Prices $110M Private Offering of Convertible Notes,2013-01-17 08:07:00-05:00,PCRX,neutral
990137.0,Pacira Pharmaceuticals Announces Proposed Offering of $100 Million of Convertible Senior Notes ,2013-01-15 16:00:00-05:00,PCRX,neutral
990138.0,Pacira Pharamaceuticals Reports Q3 EPS $-0.49 vs $-0.44 Est; Revenues $8.49M vs $7.85M Est,2012-11-01 09:15:00-04:00,PCRX,neutral
990139.0,From Earlier: Pacira Says Statistical Significance Seen at Primary Endpoints,2012-10-08 07:50:00-04:00,PCRX,positive
990140.0,"Wedbush Securities Maintains Pacira Pharamaceuticals at Outperform, Raises PT from $18 to $23",2012-09-11 13:34:00-04:00,PCRX,positive
990141.0,"Pacira Pharmaceuticals Reports Reduced Pain, Opioid Use, and Opioid-Related Adverse Events in Patients Receiving EXPAREL ",2012-09-05 07:01:00-04:00,PCRX,negative
990142.0,"Barclays Maintains Pacira Pharamaceuticals at Overweight, Raises PT from $12 to $19",2012-08-14 12:10:00-04:00,PCRX,negative
990143.0,"Jefferies & Company Maintains Pacira Pharamaceuticals at Buy, Raises PT from $18 to $22",2012-08-10 06:30:00-04:00,PCRX,neutral
990144.0,"Wedbush Securities Raises PT on Pacira Pharmaceuticals from $15 to $18, Maintains Outperform",2012-06-20 11:06:00-04:00,PCRX,positive
990145.0,Pacira Pharmaceuticals Announces Full Exercise of Overallotment Option by Underwriters   ,2012-04-25 09:02:00-04:00,PCRX,neutral
990146.0,"Wedbush Securities Maintains Pacira Pharamaceuticals at Outperform, Lowers PT from $18 to $15",2012-04-23 11:48:00-04:00,PCRX,positive
990147.0,Pacira Pharmaceuticals Prices Public Offering of 6M Shares Common Stock at $9.75/Share,2012-04-12 09:18:00-04:00,PCRX,positive
990148.0,Pacira Pharma Reports Proposed Offering of Stock,2012-04-11 16:01:00-04:00,PCRX,neutral
990149.0,"Wedbush Securities Maintains Pacira Pharamaceuticals at Outperform, Raises PT from $16 to $18",2012-04-09 12:04:00-04:00,PCRX,positive
990150.0,Pacira Pharmaceuticals Announces Commercial Availability of EXPAREL,2012-04-09 06:42:00-04:00,PCRX,neutral
990151.0,UPDATE: Piper Jaffray Raises Pacira Pharmaceuticals' PT,2012-03-28 07:47:00-04:00,PCRX,neutral
990152.0,"Piper Jaffray Maintains Pacira Pharamaceuticals at Overweight, Raises PT from $11 to $15",2012-03-28 06:50:00-04:00,PCRX,negative
990153.0,Pacira Pharma Registers for $150M Mixed Securities Shelf Offering,2012-03-27 17:39:00-04:00,PCRX,positive
990154.0,Earnings Scheduled For March 27,2012-03-27 04:05:00-04:00,PCRX,neutral
990155.0,Pacira Pharmaceuticals Announces EXPAREL Expected to be Commercially Available in April 2012   ,2012-01-09 06:51:00-05:00,PCRX,neutral
990156.0,Pacira Pharmaceuticals Announces Results from EXPAREL Pivotal Trial Published in Diseases of the Colon & Rectum ,2011-12-19 06:52:00-05:00,PCRX,neutral
990157.0,Piper Jaffray Lowers PT on Pacira Pharmaceuticals to $11,2011-11-28 10:55:00-05:00,PCRX,negative
990158.0,"Pacira Pharmaceuticals, Inc. Announces Completion of Follow-on Offering of Common Stock and Exercise of Over-Allotment Option ",2011-11-22 06:48:00-05:00,PCRX,neutral
990159.0,How Will Congress' Budget Cuts Affect Health Care?,2011-11-21 13:23:00-05:00,PCRX,positive
990160.0,Pacira Pharmaceuticals Announces Pricing of Follow-On Offering; 7M Shares at $6.50/Share,2011-11-16 06:50:00-05:00,PCRX,positive
990161.0,Benzinga's Top Pre-Market Gainers,2011-10-31 08:08:00-04:00,PCRX,positive
990162.0,"Financial Breakfast: Morning News Summary for October 31, 2011",2011-10-31 07:52:00-04:00,PCRX,neutral
990163.0,A Peek Into The Market Before The Trading Starts,2011-10-31 07:34:00-04:00,PCRX,neutral
990164.0,"Pacira Pharmaceuticals, Inc. Announces U.S. FDA Approval of EXPAREL For Postsurgical Pain Management ",2011-10-31 06:30:00-04:00,PCRX,negative
990165.0,Pacira Pharmaceuticals Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL Compared to Bupivacaine HCl  ,2011-10-19 16:10:00-04:00,PCRX,negative
990166.0,Pacira Pharmaceuticals Hopes to Avoid Pain with Exparel PDUFA,2011-10-12 12:14:00-04:00,PCRX,negative
990167.0,"Pacira Pharmaceuticals Announces Efficacy and Safety of EXPAREL Highlighted at ""Hot Topics in Plastic Surgery"" Panel",2011-09-26 06:35:00-04:00,PCRX,positive
990168.0,Top Narrow Based Indexes For September 6,2011-09-06 10:29:00-04:00,PCRX,positive
990169.0,Pacira Pharmaceuticals Expands EXPAREL Commercial Team Infrastructure  ,2011-09-06 07:00:00-04:00,PCRX,positive
990170.0,"Piper Jaffray Reiterates Rating, PT On PCRX",2011-06-15 08:20:00-04:00,PCRX,neutral
990171.0,Morning Market Losers ,2011-06-14 10:03:00-04:00,PCRX,negative
990172.0,"Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL PDUFA Target Date by Three Months",2011-06-14 06:50:00-04:00,PCRX,neutral
990173.0,"Stocks we are watching on 4/28- AMZN, LVLT, NFLX, BIDU, ORCL, YRCW, AMD, GS, POT, FCX, SNDK, IRE, AIB, CIGX, CTIC, AKAM, WFMI",2011-04-28 09:09:00-04:00,PCRX,neutral
990174.0,Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL for Postsurgical Pain Relief ,2011-02-15 16:24:00-05:00,PCRX,positive
990175.0,Pacira Pharmaceuticals IPO Priced at $7 per Share,2011-02-03 08:35:00-05:00,PCRX,positive
